Related Experiment Video
Updated: Apr 17, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.7K
Emerging oral drugs for psoriasis
Tahmina Mahmood1, Daniel Zaghi, Alan Menter
1Texas A&M Health Science Center College of Medicine , 8447 Texas 47, Bryan, TX 77807 , USA.
Expert Opinion on Emerging Drugs
|February 4, 2015
Summary
New oral treatments for moderate-to-severe psoriasis are needed, as development has lagged behind biologics. This review covers emerging oral therapies for psoriasis, addressing the ongoing need for safe, long-term options.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Psoriasis is a chronic, immune-mediated inflammatory disease.
- Characterized by erythematous plaques, it frequently affects nails and joints.
- While topical treatments suffice for some, 25% require systemic or biologic therapy.
Purpose of the Study:
- To review emerging oral treatments for moderate-to-severe psoriasis.
- To highlight the gap in oral agent development compared to biologics.
Main Methods:
- Review of current literature on oral therapies for psoriasis.
- Focus on emerging oral agents and their potential.
Main Results:
- Biologic therapies have advanced significantly.
- Oral treatments for psoriasis remain limited, including methotrexate, acitretin, cyclosporine, and apremilast.
- Development of new oral agents has lagged behind biologics.
Conclusions:
- Apremilast is a recent FDA-approved oral treatment.
- There is an unmet need for novel, safe, and effective long-term oral therapies for moderate-to-severe psoriasis.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
2.3K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.3K
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
2.1K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
2.1K
01:11Oral Drug Delivery Systems: Delayed-Release Systems
184
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
184
01:23Oral Drug Delivery Systems: Introduction
247
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
247
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
623
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
623
01:29Drugs for Treatment of Ulcerative Colitis in IBD
668
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
668